Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Annexon (Nasdaq: ANNX) granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options for an aggregate 335,000 common shares.
The options have a ten-year term and an exercise price of $6.50 per share, equal to the July 15, 2026 closing price. Vesting occurs over four years: 25% after one year, then 1/48 of the shares monthly, subject to continued service.
Positive
- None.
Negative
- None.
News Explained
The release describes rights to purchase 335,000 common shares, with vesting and exercise terms, rather than reporting that those shares were issued; any ownership change therefore depends on later exercise.
News Market Reaction – ANNX
In the Jul 17 session, ANNX declined 1.53%, reflecting a mild negative market reaction. Argus tracked a trough of -6.8% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 14 | Clinical trial update | Positive | +17.1% | Phase 2 ARCHER data presentation on vonaprument in geographic atrophy at ASRS. |
| Jun 16 | Inducement option grants | Neutral | +9.3% | Inducement stock options for 705,000 shares at $4.64 under 2022 plan. |
| May 27 | Conference participation | Neutral | -2.4% | CEO slated for fireside chats at two June 2026 healthcare conferences. |
| May 18 | Inducement option grants | Neutral | -1.0% | Equity inducement options for 243,000 shares at $5.21 to new employees. |
| May 07 | 1Q26 earnings report | Positive | +3.1% | Q1 2026 results with $225.0M cash and runway into second half 2027. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across recent announcements, including clinical and earnings updates, the stock has more often reacted positively than negatively to news flow.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the two new non-executive employees received options to purchase 335,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
